Overview

Delayed Start to Ovarian Stimulation

Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
0
Participant gender:
Female
Summary
In couples with infertility secondary to Diminished Ovarian Reserve, the investigators hypothesize that a delayed start (7 day) to ovarian stimulation with an GnRH antagonist (Ganirelix) will improve oocyte maturation and quality, and improve pregnancy outcomes.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Ganirelix
Criteria
Inclusion Criteria:

- Antral Follicle Count (AFC) less than or equal to 4 as measured by transvaginal
ultrasound (TVUS), or

- Cancellation of a prior IVF cycle due to poor ovarian response.

- Patients will receive an antagonist stimulation protocol for IVF, or IVF with
Intracytoplasmic Sperm Injection (ICSI).

Exclusion Criteria:

- Severe male factor infertility requiring surgical intervention to obtain sperm

- Major uterine abnormality,

- Preimplantation genetic diagnostic (PGD) testing,

- Planned cycles without embryo transfer (for example, freeze-all, donor, or surrogate
cycles).